Want to see SG:9G2 full AI Analyst Report?
9G2 Stock Chart & Stats
S$0.03
>-S$0.01(-3.45%)
At close: 4:00 PM EDT
S$0.03
>-S$0.01(-3.45%)
Day’s Range― - ―
52-Week RangeS$0.03 - S$0.08
Previous CloseN/A
Volume50.00K
Average Volume (3M)247.96K
Market Cap
S$48.27M
Enterprise ValueS$100.88M
Total Cash (Recent Filing)S$2.48M
Total Debt (Recent Filing)S$58.62M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,724,092,500
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA ~95% revenue jump in 2025 shows the business can attract material demand and expand its addressable activity. That larger top-line base improves the potential for operating leverage and scale economics over time, making a path to profitability more achievable if management controls overhead and cash burn.
Very High Gross MarginsSustained gross margins near 92% indicate strong unit economics or pricing power in core services, creating a wide buffer to absorb fixed and overhead costs. This structural margin profile supports profit conversion potential if SG&A and other operating costs are disciplined going forward.
Positive Equity / Asset CushionMaintaining positive shareholders' equity and a sizable asset base provides a balance-sheet cushion that supports continued operation and financing optionality. This gives management time to execute a turnaround, access collateralized financing, or monetize assets rather than facing immediate solvency pressure.
Bears Say
Deep Persistent LossesVery large net losses across years signal structural unprofitability that revenue growth alone may not cure. Such losses erode retained capital, depress returns on equity, and require recurring external funding or drastic cost restructuring, creating lasting execution and dilution risk if not reversed.
Consistent Negative Cash FlowPersistent negative operating and free cash flow indicates ongoing cash burn and reliance on external financing to fund operations. This reduces financial flexibility, increases refinancing and dilution risk, and constrains the company's ability to invest in growth or sustain operations until cash generation turns positive.
Elevated, Rising LeverageMeaningful and rising leverage alongside losses increases interest and covenant pressure and limits strategic flexibility. High debt levels make financing costlier and heighten refinancing risk, reducing the company's ability to fund growth, absorb shocks, or pursue strategic investments until leverage declines.
Singapore Institute of Advanced Medicine Holdings Ltd. News
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.03 and its highest was S$0.08 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$48.27M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 92 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on May 14, 2026. The company reported -S$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.004.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,724,092,500 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.522%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company primarily focused on delivering healthcare services. Its operations include providing pharmaceutical products, surgical supplies, and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011, and is headquartered in Singapore.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) Earnings & Revenues
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
HC Surgical Specialists Ltd
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―